By inducing SHP2 degradation and inhibiting the MAPK signaling pathway, R1-5C effectively suppresses leukemic cell growth and offers a therapeutic option for treating ERK-dependent cancers (Table 4).500. The gene discussed is PTPN11; the disease is cancer.